Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.

Xia W, Yu H, Lei X, Wen P

Medicine1 Mar 2024Cited by 7 (Europe PMC)

PMID38489694PMCIDPMC10939689DOI10.1097/md.0000000000037432PepBankPUB-38489694

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly improved left ventricular ejection fraction versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide improved the heart's pumping fraction compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
IncreaseLeft ventricular ejection fraction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.38 SMD
left ventricular ejection fraction
Source sentences
Summary
Results revealed that liraglutide exhibited significant enhancements in left ventricular ejection fraction [SMD = -0.38, 95%CI(-0.70, -0.06), P = .02]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969401
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly improved cardiac index versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide improved cardiac index compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
IncreaseCardiac index
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−1.05 SMD
cardiac index
Source sentences
Summary
cardiac index [SMD = -1.05, 95%CI(-1.52, -0.59), P < .0001]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969402
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly improved stroke volume versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide improved stroke volume compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
IncreaseStroke volume
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.67 SMD
stroke volume
Source sentences
Summary
stroke volume [SMD = -0.67, 95%CI(-1.02, -0.32), P = .0002]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969403
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly improved the early to late diastolic filling velocity ratio versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide improved a heart filling measure compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
IncreaseEarly diastolic filling velocity/late atrial filling velocity ratio
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.52 SMD
early diastolic filling velocity/late atrial filling velocity ratio
Source sentences
Summary
early diastolic filling velocity/late atrial filling velocity ratio [SMD = -0.52, 95%CI(-0.82, -0.22), P = .0006]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969404
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide had no statistically significant effect on cardiac output versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change cardiac output compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
No significant changeCardiac output
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.2 SMD
cardiac output
Source sentences
Summary
no statistically significant impact on cardiac output [SMD = -0.20, 95%CI(-0.53, 0.14), P = .26]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969405
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide had no statistically significant effect on the E/Ea ratio versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change a heart filling-pressure measure compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
No significant changeE/Ea ratio
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.34 SMD
E/Ea ratio
Source sentences
Summary
early diastolic filling velocity/early diastolic annular velocity (E/Ea) ratio [SMD = -0.34, 95%CI(-0.75, 0.06), P = .10]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969406
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide had no statistically significant effect on the early diastolic filling velocity to mitral annular velocity ratio versus placebo in a meta-analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change another heart filling measure compared with placebo in a pooled analysis of trials.
Peptide
Liraglutide
Outcome
No significant changeEarly diastolic filling velocity/early diastolic mitral annular velocity ratio
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
0.21 SMD
early diastolic filling velocity/early diastolic mitral annular velocity ratio
Source sentences
Summary
early diastolic filling velocity/early diastolic mitral annular velocity ratio [SMD = 0.21, 95%CI(-0.15, 0.56), P = .25]
2 context sentences(design, population, supporting numbers)
Summary · context
We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes.
Summary · context
The meta-analysis encompassed 5 RCTs including 220 participants.
Report a problemFND-3848969407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.